100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R43GM135985
Award Date
2/15/20
Completion Date
8/14/21
Dollars Obligated
$225K
Overview
Activity
3
Transactions
3
Subawards
Similar Awards
Federal Agency
National Institute of General Medical Sciences
Awardee
Instadiagnostics Inc. (RMAKJENJ3NQ9)
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Update #1
Update #2
A RAPID MULTIPLEXED TEST FOR THE SCREENING OF SEPSIS AND ORGAN DYSFUNCTION AT THE POINT OF CARE
Posted 2/5/20
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
A RAPID MULTIPLEXED TEST FOR THE SCREENING OF SEPSIS AND ORGAN DYSFUNCTION AT THE POINT OF CARE - ABSTRACT INSTADIAGNOSTICS (IDI) IS DEVELOPING A POINT-OF-CARE (POC) DIAGNOSTIC TECHNOLOGY PLATFORM WITH THE GOAL OF PROVIDING EARLY DETECTION, SCREENING, AND TREATMENT MONITORING FOR PATIENTS AT PRIMARY CARE CENTERS, COMMUNITY CLINICS, URGENT CARE CENTERS, AND EMERGENCY DEPARTMENTS. THE DEVICE CONSISTS OF A PORTABLE READER (THE INSTAREADER) AND DISPOSABLE CARTRIDGES (INSTACARTRIDGE). A RANGE OF DISEASE SPECIFIC CARTRIDGES WILL ALLOW FOR MULTIPLE DISEASES BE DETECTED ON A SINGLE DEVICE. THE SYSTEM'S ABILITY TO PROVIDE CLINICAL LABORATORY QUALITY RESULTS IN LESS THAN 15 MINUTES WILL GIVE MEDICAL WORKERS THE CAPABILITY TO IMMEDIATELY DIAGNOSE PATIENTS, AND ALLOWS PATIENTS TO AVOID ADDITIONAL TRIPS TO HAVE BLOOD DRAWN, LENGTHY WAIT TIMES FOR RESULTS, OR DELAYS IN DIAGNOSIS AND FOLLOW UP TESTING. IDI'S DIAGNOSTIC PLATFORM WILL IMPROVE PATIENT CARE/SATISFACTION, MEDICAL OUTCOMES, AND WORKFLOW FOR HEALTHCARE PROVIDERS, WHILE REDUCING OVERALL MEDICAL COSTS. SEPSIS IS DEFINED AS LIFE-THREATENING ORGAN DYSFUNCTION CAUSED BY A DYSREGULATED HOST RESPONSE TO INFECTION. ORGAN DYSFUNCTION IS CLOSELY ASSOCIATED WITH SEPSIS AND IT IS RARE THAT JUST A SINGLE ORGAN IS IMPACTED, THE HIGHER NUMBER OF ORGANS IMPACTED THE HIGHER IS THE RISK FOR MORTALITY. GLOBALLY SEPSIS IS THE MOST PREVENTABLE CAUSE OF DEATH AND DISABILITY, WITH OVER 30 MILLION CASES DIAGNOSED ANNUALLY AND 6 MILLION DEATHS. IN THE U.S. THE CDC ESTIMATES THAT THERE ARE APPROXIMATELY 1.7 MILLION CASES AND 270,000 DEATHS ANNUALLY. THERE IS STRONG EVIDENCE THAT IF DIAGNOSED EARLY, SEPSIS IS LARGELY PREVENTABLE AND ORGAN DYSFUNCTION IS REVERSIBLE. BLOOD TESTS FOR INFECTION, INFLAMMATION, AND ORGAN DYSFUNCTION CAN AID IN THE SCREENING AND EARLY DIAGNOSIS OF SEPSIS, ESPECIALLY IN PRIMARY CARE FACILITIES. HOWEVER, MOST OF THESE TESTS ARE PERFORMED IN CENTRALIZED LABORATORIES AND IT CAN TAKE HOURS OR EVEN DAYS TO GET THE RESULTS ALLOWING FOR THE PROGRESSION TO SEVERE SEPSIS AND ORGAN FAILURE. THEREFORE, AN IMPROVED, MULTIPLEXED TEST, FOR SCREENING HIGH-RISK INDIVIDUALS FOR SEPSIS AND ORGAN DYSFUNCTION PERFORMED IMMEDIATELY AT THE POC, IS ESSENTIAL TO IMPROVE PROGNOSIS FOR THESE INDIVIDUALS. OUR OVERALL SEPSIS GOAL IS TO DEVELOP A MULTIPLEXED TEST FOR PROCALCITONIN (PCT), C-REACTIVE PROTEIN (CRP), LACTATE, CREATININE, BILIRUBIN, BLOOD UREA NITROGEN, FIBRINOGEN, AND D-DIME. THIS PHASE I WILL BE FOCUSED ON: AIM 1: DEVELOP AND CHARACTERIZE ASSAYS FOR PCT, CRP, LACTATE AND CREATININE AIM 2: DEVELOPMENT OF A MULTI-TECHNOLOGY BREAD-BOARD READER AND MULTIPLEXED CARTRIDGE TO SIMULTANEOUSLY MEASURE LEVELS OF PCT, CRP, LACTATE, AND CREATININE IN THE SAME SAMPLE PHASE II WILL FOCUS ON EXPANDING ON THE PANEL, AND CONDUCTING A PILOT CLINICAL STUDY TO DEMONSTRATE THE PERFORMANCE AND UTILITY OF THE TEST. IT WILL THEN BE FOLLOWED WITH ORGAN SPECIFIC PANELS FOR FURTHER PATIENT EVALUATION.
$0
3/3/22
Not listed
A RAPID MULTIPLEXED TEST FOR THE SCREENING OF SEPSIS AND ORGAN DYSFUNCTION AT THE POINT OF CARE - ABSTRACT INSTADIAGNOSTICS (IDI) IS DEVELOPING A POINT-OF-CARE (POC) DIAGNOSTIC TECHNOLOGY PLATFORM WITH THE GOAL OF PROVIDING EARLY DETECTION, SCREENING, AND TREATMENT MONITORING FOR PATIENTS AT PRIMARY CARE CENTERS, COMMUNITY CLINICS, URGENT CARE CENTERS, AND EMERGENCY DEPARTMENTS. THE DEVICE CONSISTS OF A PORTABLE READER (THE INSTAREADER) AND DISPOSABLE CARTRIDGES (INSTACARTRIDGE). A RANGE OF DISEASE SPECIFIC CARTRIDGES WILL ALLOW FOR MULTIPLE DISEASES BE DETECTED ON A SINGLE DEVICE. THE SYSTEM'S ABILITY TO PROVIDE CLINICAL LABORATORY QUALITY RESULTS IN LESS THAN 15 MINUTES WILL GIVE MEDICAL WORKERS THE CAPABILITY TO IMMEDIATELY DIAGNOSE PATIENTS, AND ALLOWS PATIENTS TO AVOID ADDITIONAL TRIPS TO HAVE BLOOD DRAWN, LENGTHY WAIT TIMES FOR RESULTS, OR DELAYS IN DIAGNOSIS AND FOLLOW UP TESTING. IDI'S DIAGNOSTIC PLATFORM WILL IMPROVE PATIENT CARE/SATISFACTION, MEDICAL OUTCOMES, AND WORKFLOW FOR HEALTHCARE PROVIDERS, WHILE REDUCING OVERALL MEDICAL COSTS. SEPSIS IS DEFINED AS LIFE-THREATENING ORGAN DYSFUNCTION CAUSED BY A DYSREGULATED HOST RESPONSE TO INFECTION. ORGAN DYSFUNCTION IS CLOSELY ASSOCIATED WITH SEPSIS AND IT IS RARE THAT JUST A SINGLE ORGAN IS IMPACTED, THE HIGHER NUMBER OF ORGANS IMPACTED THE HIGHER IS THE RISK FOR MORTALITY. GLOBALLY SEPSIS IS THE MOST PREVENTABLE CAUSE OF DEATH AND DISABILITY, WITH OVER 30 MILLION CASES DIAGNOSED ANNUALLY AND 6 MILLION DEATHS. IN THE U.S. THE CDC ESTIMATES THAT THERE ARE APPROXIMATELY 1.7 MILLION CASES AND 270,000 DEATHS ANNUALLY. THERE IS STRONG EVIDENCE THAT IF DIAGNOSED EARLY, SEPSIS IS LARGELY PREVENTABLE AND ORGAN DYSFUNCTION IS REVERSIBLE. BLOOD TESTS FOR INFECTION, INFLAMMATION, AND ORGAN DYSFUNCTION CAN AID IN THE SCREENING AND EARLY DIAGNOSIS OF SEPSIS, ESPECIALLY IN PRIMARY CARE FACILITIES. HOWEVER, MOST OF THESE TESTS ARE PERFORMED IN CENTRALIZED LABORATORIES AND IT CAN TAKE HOURS OR EVEN DAYS TO GET THE RESULTS ALLOWING FOR THE PROGRESSION TO SEVERE SEPSIS AND ORGAN FAILURE. THEREFORE, AN IMPROVED, MULTIPLEXED TEST, FOR SCREENING HIGH-RISK INDIVIDUALS FOR SEPSIS AND ORGAN DYSFUNCTION PERFORMED IMMEDIATELY AT THE POC, IS ESSENTIAL TO IMPROVE PROGNOSIS FOR THESE INDIVIDUALS. OUR OVERALL SEPSIS GOAL IS TO DEVELOP A MULTIPLEXED TEST FOR PROCALCITONIN (PCT), C-REACTIVE PROTEIN (CRP), LACTATE, CREATININE, BILIRUBIN, BLOOD UREA NITROGEN, FIBRINOGEN, AND D-DIME. THIS PHASE I WILL BE FOCUSED ON: AIM 1: DEVELOP AND CHARACTERIZE ASSAYS FOR PCT, CRP, LACTATE AND CREATININE AIM 2: DEVELOPMENT OF A MULTI-TECHNOLOGY BREAD-BOARD READER AND MULTIPLEXED CARTRIDGE TO SIMULTANEOUSLY MEASURE LEVELS OF PCT, CRP, LACTATE, AND CREATININE IN THE SAME SAMPLE PHASE II WILL FOCUS ON EXPANDING ON THE PANEL, AND CONDUCTING A PILOT CLINICAL STUDY TO DEMONSTRATE THE PERFORMANCE AND UTILITY OF THE TEST. IT WILL THEN BE FOLLOWED WITH ORGAN SPECIFIC PANELS FOR FURTHER PATIENT EVALUATION.
$0
3/3/22
Not listed
A RAPID MULTIPLEXED TEST FOR THE SCREENING OF SEPSIS AND ORGAN DYSFUNCTION AT THE POINT OF CARE
$225.0k
2/5/20